News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Thomas Dietz, Ph.D., Elected Chairman of Galleon Pharmaceuticals, Inc.



10/26/2011 11:52:51 AM

HORSHAM, Pa., Oct. 26, 2011 /PRNewswire/ -- Galleon Pharmaceuticals, a leader in the pharmaceutical treatment of breathing-control disorders, announced today that its board of directors has elected Thomas J. Dietz, Ph.D., as the company's chairman. Dr. Dietz is chairman and CEO of Waypoint Holdings, LLC, a diversified financial-holdings and services company.

Previously, Dr. Dietz was co-CEO and then CEO and a director of Pacific Growth Equities, LLC, a San Francisco-based investment bank and institutional brokerage firm from 2004 to 2009, when the firm was acquired by Wedbush Securities. Dr. Dietz served as head of the investment banking division at Wedbush until November 2010.

Prior to taking the CEO role at Pacific Growth, Dr. Dietz served as the company's director of equities research and was an award-winning biotechnology and biopharmaceutical analyst. He joined Pacific Growth in 1993. Previously, he was a member of the research faculty in the Department of Medicine, University of California, San Francisco and the VA Medical Center. Dr. Dietz is a member of several national societies and currently serves on the boards of trustees of several non-profit organizations, including the West Bay Region board of the Sutter Health System that includes California Pacific Medical Center, San Francisco.

Dr. Dietz holds a Ph.D. in molecular biology and biochemistry from Washington University, St. Louis, and was a National Science Foundation Post-Doctoral Fellow.

About Galleon Pharmaceuticals

Galleon is the first pharmaceutical company to focus primarily on the drug treatment of breathing-control disorders. Its initial goals are to improve the safety, efficacy and economics associated with the acute care of surgical patients and longer-term care of patients with conditions such as moderate-to-severe pain or sleep apnea. In the United States alone, it is estimated that 100 million patients are at risk for a breathing-control disorder due to drugs, diseases or genetics.

The company's product pipeline reflects recent advances in neurobiology, molecular biology and respiratory medicine which have enabled the development of a unique drug-discovery platform and promising drug candidates that are now undergoing clinical trials. Galleon's integrated discovery and development approach is unique among pharmaceutical companies and enables the rapid evaluation of multiple variables to establish a comprehensive profile of breathing-control activity. For more information, please visit www.galleonpharma.com.

SOURCE Galleon Pharmaceuticals


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES